INVENTIVA SA - ADR
IVANASDAQTrading Snapshot
- Day Range
- $3.66 – $3.75
- 52-Week Range
- $2.82 – $7.98
- Volume (shares)
- 946,889
- Avg Volume (shares)
- —
- Shares Outstanding
- 52.0M
- Next Earnings
- 2027-02-18
Fundamentals Snapshot
- Annual Revenue
- $4M
- Last Q Revenue
- $1M
- P/E Ratio
- -6.2
- P/S Ratio
- 15788.2x
- EPS (TTM)
- $-0.91
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1125.6%
INVENTIVA SA - ADR
IVA
StockOtter · stockotter.spaceAbout INVENTIVA SA - ADR
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
Inventiva receives a speculative strong buy rating, with a probability-weighted fair value of ~$15 per share versus ~$3.20 currently. Following strong Phase 2b NATIVE results, lanifibranor's pivotal Phase 3 NATiV3 readou
Inventiva (NASDAQ:IVA) Sets New 12-Month Low – Here’s What Happened
Shares of Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) reached a new 52-week low on Tuesday. The company traded as low as $3.10 and last traded at $3.12, with a volume of 3,264,826 shares traded. The stoc
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading volume.
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced new interim data from the ALYFTREKÂ (vanzacaftor/tezacaftor/deutivacaftor) 2 to
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic dysfunction-associated steatohepati
Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report)'s share price gapped down before the market opened on Thursday. The stock had previously closed at $3.69, but opened at $3.38. Inventiva shares last traded at